---
companies:
- category: unknown
  confidence: medium
  context: Welcome everyone to the AI and Business Podcast. I'm Matthew Damello, editorial
    director here at
  name: Business Podcast
  position: 31
- category: unknown
  confidence: medium
  context: come everyone to the AI and Business Podcast. I'm Matthew Damello, editorial
    director here at Emerge AI Research. T
  name: Matthew Damello
  position: 53
- category: unknown
  confidence: medium
  context: . I'm Matthew Damello, editorial director here at Emerge AI Research. Today's
    guest is Michael Zayak, Head of Medical
  name: Emerge AI Research
  position: 97
- category: unknown
  confidence: medium
  context: ctor here at Emerge AI Research. Today's guest is Michael Zayak, Head of
    Medical Oncology for Europe and Canada a
  name: Michael Zayak
  position: 134
- category: unknown
  confidence: medium
  context: Research. Today's guest is Michael Zayak, Head of Medical Oncology for
    Europe and Canada at Daiichi Sankyo. Daiichi
  name: Medical Oncology
  position: 157
- category: unknown
  confidence: medium
  context: Head of Medical Oncology for Europe and Canada at Daiichi Sankyo. Daiichi
    Sankyo Company Limited is a global pharm
  name: Daiichi Sankyo
  position: 199
- category: unknown
  confidence: medium
  context: Oncology for Europe and Canada at Daiichi Sankyo. Daiichi Sankyo Company
    Limited is a global pharmaceutical company and the second
  name: Daiichi Sankyo Company Limited
  position: 215
- category: unknown
  confidence: medium
  context: ecutive thought leaders, everyone from the CIO of Goldman Sachs to the
    Head of AI at Raytheon and AI pioneers lik
  name: Goldman Sachs
  position: 1521
- category: unknown
  confidence: medium
  context: o the Head of AI at Raytheon and AI pioneers like Yoshua Bengio. With nearly
    a million annual listeners, AI and B
  name: Yoshua Bengio
  position: 1586
- category: unknown
  confidence: medium
  context: eve you can help other leaders move the needle on AI ROI, visit emerj.com
    and fill out our Thought Leaders
  name: AI ROI
  position: 2052
- category: unknown
  confidence: medium
  context: eedle on AI ROI, visit emerj.com and fill out our Thought Leaders submission
    form. That's emerj.com and click on Be
  name: Thought Leaders
  position: 2093
- category: unknown
  confidence: medium
  context: posal of life sciences leaders and organizations. Generative AI is more
    than on the horizon right now. I think fo
  name: Generative AI
  position: 5290
- category: unknown
  confidence: medium
  context: ervative place to operate. It's highly regulated. And I very much recall
    an interview or podcast Sam Altm
  name: And I
  position: 6196
- category: unknown
  confidence: medium
  context: d. And I very much recall an interview or podcast Sam Altman gave sometime
    in 2024, where he referred to the p
  name: Sam Altman
  position: 6243
- category: unknown
  confidence: medium
  context: ecision we deploy, which comes with restrictions. As I said, when we take
    a large language model, we mak
  name: As I
  position: 10406
- category: unknown
  confidence: medium
  context: And I think other industries can learn from that. So I think that means
    the outcomes are then truly acce
  name: So I
  position: 11412
- category: unknown
  confidence: medium
  context: you make a differentiation between Europe and the United States, which
    I very much appreciate, but I would hate f
  name: United States
  position: 14515
- category: unknown
  confidence: medium
  context: ve side. We work very closely with experts on the AI Act, which of course
    has been implemented recently. A
  name: AI Act
  position: 15751
- category: unknown
  confidence: medium
  context: hat we do. So we go in excess of what the current EU AI Act actually requires
    by choosing always automaticall
  name: EU AI Act
  position: 16024
- category: unknown
  confidence: medium
  context: less the same song sheet, as our CEO and Head of Research Dan Fichella
    at Emerge loves to say. But very, very fascinatin
  name: Research Dan Fichella
  position: 16621
- category: ai_research
  confidence: high
  context: The organization hosting the podcast and employing the host/editorial director.
  name: Emerge AI Research
  source: llm_enhanced
- category: ai_application
  confidence: high
  context: A global pharmaceutical company using AI (deterministic and generative)
    to accelerate clinical trial recruitment and improve eligibility precision.
  name: Daiichi Sankyo Company Limited
  source: llm_enhanced
- category: ai_infrastructure
  confidence: high
  context: The sponsor of the podcast episode.
  name: Metable
  source: llm_enhanced
- category: big_tech
  confidence: medium
  context: Mentioned as an example of an organization whose CIO has been featured
    on the podcast, indicating enterprise AI adoption.
  name: Goldman Sachs
  source: llm_enhanced
- category: ai_application
  confidence: medium
  context: Mentioned as an example of an organization whose Head of AI has been featured
    on the podcast, indicating enterprise AI adoption.
  name: Raytheon
  source: llm_enhanced
- category: ai_research
  confidence: high
  context: Mentioned as an AI pioneer featured on the podcast, implying association
    with leading AI research/development.
  name: Yoshua Bengio
  source: llm_enhanced
- category: ai_research
  confidence: high
  context: Mentioned for giving an interview/podcast where he referred to the pharmaceutical
    industry regarding AI adoption timelines.
  name: Sam Altman
  source: llm_enhanced
- category: ai_research
  confidence: high
  context: CEO and Head of Research at Emerge, mentioned in context of industry discussion.
  name: Dan Fichella
  source: llm_enhanced
- category: ai_application
  confidence: high
  context: The organization where the speaker and Head of Research Dan Fichella work,
    focused on AI application, likely in regulated industries.
  name: Emerge
  source: llm_enhanced
- category: organization
  confidence: high
  context: The podcast hosting the conversation about real-world AI adoption.
  name: AI and Business Podcast
  source: llm_enhanced
date: 2025-07-09 07:00:00 +0000
duration: 25
has_transcript: false
layout: episode
llm_enhanced: true
original_url: https://traffic.libsyn.com/secure/techemergence/Business_-_7.9.25_-_Michael_Zaiac.mp3?dest-id=151434
processing_date: 2025-10-05 03:36:52 +0000
quotes:
- length: 172
  relevance_score: 5
  text: That was for me the most important learning, not so much for the alternative
    AI, but as soon as we move to a generative AI, you need to bring on board all
    your stakeholders
  topics: []
- length: 148
  relevance_score: 4
  text: First, are you driving AI transformation at your organization, or maybe you're
    guiding critical decisions on AI investments, strategy, or deployment
  topics:
  - investment
- length: 123
  relevance_score: 4
  text: And finally, effective AI adoption in pharma requires early alignment across
    legal, compliance, and regulatory stakeholders
  topics: []
- length: 141
  relevance_score: 4
  text: Are you driving AI transformation at your organization, or maybe you're guiding
    critical decisions on AI investments, strategy, or deployment
  topics:
  - investment
- length: 230
  relevance_score: 3
  text: This isn't just about the end of the drug development life cycle, but really
    that ending having full visibility over the entire value chain and knowing where
    we can drive all kinds of artificial intelligence throughout the process
  topics: []
- impact_reason: Directly addresses the critical issue of AI bias, noting the awareness
    and mitigation strategies, especially concerning Generative AI amplifying historical
    data biases.
  relevance_score: 10
  source: llm_enhanced
  text: we are aware of it [bias] and we fear it. I think when we use the generative
    AI part, we haven't really seen it when we deploy our models or anything in patient
    selection, but we of course check for that, that the machine doesn't have a bias
    because of course it amplifies the human bias of the data it has been fed with...
  topic: safety/ethics
- impact_reason: 'Provides a concrete mitigation strategy for GenAI risk: restricting
    powerful LLMs to be ''more basic, but hence much more precise'' for regulated
    tasks.'
  relevance_score: 10
  source: llm_enhanced
  text: In advanced analytics, this seems to be less of an issue. In generative AI,
    we are very much aware of it, and that is what I meant earlier. We have built
    workbenches and filters in which restrict existing large language models to a
    much more basic, but hence much more precise machine.
  topic: safety/technical
- impact_reason: 'This is a core strategic takeaway for AI deployment in high-stakes
    environments: intentional constraint leads to higher precision and safety.'
  relevance_score: 10
  source: llm_enhanced
  text: I think it's the precision we deploy, which comes with restrictions. As I
    said, when we take a large language model, we make it less rather than more, but
    we make it less with intent, be restricted with intent.
  topic: strategy/safety
- impact_reason: 'Identifies the critical bottleneck in AI deployment: data quality
    and availability, specifically the lack of collaboration among data providers,
    overriding technological capability.'
  relevance_score: 10
  source: llm_enhanced
  text: What isn't there is the collaboration of data providers. We don't have the
    quality of the data for the quality of the software we have.
  topic: technical
- impact_reason: 'Provides a concrete example of proactive, best-practice compliance
    strategy regarding the EU AI Act: automatically defaulting to the highest risk
    category.'
  relevance_score: 10
  source: llm_enhanced
  text: We work very closely with experts on the AI Act, which of course has been
    implemented recently. A lot of it makes sense. I mean, it differentiates very
    clearly by risk levels, and we plan as an organization to always automatically
    apply the highest risk level to what we do. So we go in excess of what the current
    EU AI Act actually requires by choosing always automatically the highest risk
    level.
  topic: safety/regulation
- impact_reason: Strong warning about the necessity of stakeholder buy-in for generative
    AI projects, linking lack of transparency ('black box') directly to implementation
    failure.
  relevance_score: 10
  source: llm_enhanced
  text: As soon as we move to a generative AI, you need to bring on board all your
    stakeholders. You're not in isolation, you will fail. They will block you for
    good reasons because they don't understand the black box, they will block you.
  topic: strategy
- impact_reason: 'This clearly defines the core value proposition of deterministic
    AI (advanced analytics/ML) in clinical trials: speed and improved patient diversity
    through pattern matching in EHR data.'
  relevance_score: 9
  source: llm_enhanced
  text: AI is a huge opportunity because where data exists, so where electronic health
    records exist for us and are accessible, having the pattern matching capabilities
    of machine learning brings us opportunities which we didn't have before in identifying
    the right patients for all studies quicker, but also the right patients in the
    sense of diverse patients...
  topic: technical/business
- impact_reason: Highlights the strategic importance of diverse recruitment—ensuring
    trial populations mirror the real-world patient base, which is crucial for drug
    efficacy and safety validation.
  relevance_score: 9
  source: llm_enhanced
  text: pattern matching using machine learning really helps us to find patient populations
    in our clinical studies which will resemble reality post-launch of that medicine.
  topic: strategy/safety
- impact_reason: 'Clearly demarcates the role of Generative AI in pharma: patient-facing
    content customization and simplification, contrasting it with deterministic AI''s
    role in recruitment.'
  relevance_score: 9
  source: llm_enhanced
  text: when it then comes more to patient contact, to stay being innovative in writing
    content sheets, in coming up with summaries of studies which are more patient-friendly,
    then we really talk about generative AI and the power of generative AI, of adapting
    material so that it meets patient needs better.
  topic: technical/business
- impact_reason: 'Defines the pharma approach to AI: prioritizing extreme accuracy
    and refinement over bleeding-edge deployment, which is a key lesson for regulated
    industries.'
  relevance_score: 9
  source: llm_enhanced
  text: What you see is you see AI technology being perfected to the degree of high
    levels of accuracy. I think that's what pharma is a good place for.
  topic: strategy
- impact_reason: Highlights the necessity of multi-stakeholder transparency (legal,
    compliance, regulators) as a prerequisite for AI acceptance, a lesson for all
    industries deploying complex models.
  relevance_score: 9
  source: llm_enhanced
  text: And the second thing I think other industries can learn, I think, is the effort
    we take to make the black box of AI transparent to a group of diverse stakeholders.
    Of course, we operate in a highly regulated framework, so we need to internally
    and externally make this transparent to lawyers, to compliance people, to regulators...
  topic: strategy/safety
- impact_reason: 'Clearly articulates the immediate, quantifiable ROI for deterministic
    AI in clinical trials: reduced trial duration equals massive cost savings.'
  relevance_score: 9
  source: llm_enhanced
  text: Fast ROI in advanced analytics is fairly clear because advanced analytics,
    as used in clinical trials, gives us the opportunity to quicker enroll clinical
    studies. And of course, every day we don't enroll, but we have a finalized study
    result, costs us less money.
  topic: business/ROI
- impact_reason: Provides a concrete, high-value ROI justification for deterministic
    AI/advanced analytics in the clinical trial space (faster enrollment, earlier
    filing).
  relevance_score: 9
  source: llm_enhanced
  text: ROI in advanced analytics is fairly clear because advanced analytics, as used
    in clinical trials, gives us the opportunity to quicker enroll clinical studies.
    And of course, every day we don't enroll, but we have a finalized study result,
    costs us less money. Every day we can file earlier with an agency for approval
    means we have a longer protection time on the market. So that ROI is very clear
    cut.
  topic: business
- impact_reason: A strong prediction/statement on the immediate potential of current
    AI technology to drastically accelerate critical medical processes (cutting trial
    time in half).
  relevance_score: 9
  source: llm_enhanced
  text: Technology today enables us to put the ideal trials together probably in half
    the time we needed to really satisfy the patients with an unmet medical need.
  topic: predictions
- impact_reason: Pinpoints regional differences (Europe vs. US) in data collaboration,
    attributing it to competitive behavior rather than just regulation, which is crucial
    for scaling AI.
  relevance_score: 9
  source: llm_enhanced
  text: Data and data collaboration, especially in Europe, where it's more my realm
    of operation, is less suited to achieve that. And that's something we also fight
    for, is to make people collaborate so that the data lakes are actually sufficient
    for AI.
  topic: strategy
- impact_reason: 'Actionable advice for clinical leaders starting AI adoption: overcome
    inertia and prioritize cross-functional collaboration immediately.'
  relevance_score: 9
  source: llm_enhanced
  text: I think you said it, Matthew, you need to start somewhere, have the courage
    to start, and don't start in isolation, start with your other stakeholders.
  topic: business
- impact_reason: Directly links solitary model development/usage with bias amplification,
    reinforcing the 'human in the loop' concept as a bias mitigation strategy.
  relevance_score: 9
  source: llm_enhanced
  text: If you're working with these models and generative AI platforms in solitude,
    it shares your biases, to bring back our points on biases as before. So then,
    you and the model are a little bit inseparable if it's only been started under
    you.
  topic: safety/ethics
- impact_reason: Crucial advice stressing that governance and trust-building (via
    transparency) must precede or accompany technical deployment in regulated fields.
  relevance_score: 9
  source: llm_enhanced
  text: Effective AI adoption in pharma requires early alignment across legal, compliance,
    and regulatory stakeholders. Transparency is not optional; it's essential for
    building trust and long-term success.
  topic: safety/strategy
- impact_reason: Provides a clear distinction between the current, established use
    of AI in patient identification (deterministic/advanced analytics) versus newer
    applications.
  relevance_score: 8
  source: llm_enhanced
  text: What we're using in that setting [recruitment] is what we would call advanced
    analytics, or you call it deterministic AI. It is largely advanced analytics.
  topic: technical
- impact_reason: A powerful, memorable analogy illustrating the extensive, mandatory
    pre-deployment validation and stakeholder alignment required in regulated industries
    before AI adoption.
  relevance_score: 8
  source: llm_enhanced
  text: I almost compare it to a pregnancy. So before I launch something, I spend
    nine months of growing the baby in the womb, and that's approximately truly the
    time I need to get such a project approved, sort of communicated amongst the stakeholders.
  topic: strategy
- impact_reason: Connects trial speed directly to market exclusivity and revenue protection,
    providing a high-level business justification for AI investment.
  relevance_score: 8
  source: llm_enhanced
  text: Every day we can file earlier with an agency for approval means we have a
    longer protection time on the market. So that ROI is very clear cut.
  topic: business/ROI
- impact_reason: 'Shows how ROI is calculated for emerging uses like GenAI: focusing
    on efficiency gains (saving skilled labor hours) rather than just direct revenue
    impact.'
  relevance_score: 8
  source: llm_enhanced
  text: Then when it comes to the more generative use... then we look very carefully
    at what are the man-hours used or what kind of qualified people, what are we saving
    on man-hours. So we make very calculated ROI projections.
  topic: business/ROI
- impact_reason: Highlights the shift in ROI calculation for generative AI applications—moving
    from direct cost savings (man-hours) to more complex, calculated projections.
  relevance_score: 8
  source: llm_enhanced
  text: Then when it comes to the more generative use, so when machines start writing
    protocols in clinical study, when we are talking about modifying patient information
    to make it appropriate, then we look very carefully at what are the man-hours
    used or what kind of qualified people, what are we saving on man-hours. So we
    make very calculated ROI projections.
  topic: business
- impact_reason: A candid admission about the difficulty of quantifying long-term,
    philosophical ROI for advanced AI deployments, a common challenge across industries.
  relevance_score: 8
  source: llm_enhanced
  text: Of course, for AI, especially deploying it in the long term, longer-term ROI
    is always opaque. It's always more philosophical. It's harder to tie down to dollar
    signs.
  topic: strategy
- impact_reason: Clarifies that data sharing hurdles in Europe are often driven by
    competitive behavior within the healthcare space, even when compliance (GDPR)
    is technically met.
  relevance_score: 8
  source: llm_enhanced
  text: No, I think it's GDPR in Europe and HIPAA in the US. It's correlated to compliance,
    but of course, most of these things would be very compliant. It's more the competitive
    behavior of centers which sort of block collaboration.
  topic: safety/regulation
- impact_reason: 'A pragmatic strategic insight: regulated industries should focus
    on optimizing within their constraints rather than trying to lead foundational
    AI innovation.'
  relevance_score: 8
  source: llm_enhanced
  text: We are not going to be the innovators in AI in the pharma industry, we cannot
    be. We are restricted for good reasons, and let's operate in that restricted space
    and make the best out of it.
  topic: strategy
- impact_reason: Summary takeaway emphasizing the immediate, measurable success of
    established AI/analytics methods in healthcare operations.
  relevance_score: 8
  source: llm_enhanced
  text: Deterministic AI, particularly in the form of advanced analytics, is already
    showing clear ROI by accelerating patient recruitment and improving eligibility
    matching in clinical trials.
  topic: business
- impact_reason: 'Identifies a specific, low-risk, high-value application for generative
    AI in life sciences: improving patient-facing documentation.'
  relevance_score: 8
  source: llm_enhanced
  text: While generative AI is still used cautiously in life sciences, it's playing
    a growing role in patient communications, helping teams create clearer, more accessible
    study materials that improve patient engagement.
  topic: predictions
- impact_reason: Offers a candid assessment of the pharmaceutical industry's position
    in the AI adoption curve—conservative and later-stage adopter, contrasting with
    fast-moving sectors.
  relevance_score: 7
  source: llm_enhanced
  text: I very much recall an interview or podcast Sam Altman gave sometime in 2024,
    where he referred to the pharmaceutical industry. Obviously, it's not the place
    where AI lands first.
  topic: strategy
- impact_reason: Broadens the definition of ROI beyond pure financial metrics to include
    user/employee satisfaction, a critical factor for long-term technology adoption.
  relevance_score: 7
  source: llm_enhanced
  text: The third item outside ROI or direct ROI is satisfaction. Customer satisfaction
    with the end product is getting better, and the user satisfaction. So are our
    people happy with the tool we've given them?
  topic: business/ROI
- impact_reason: Introduces 'satisfaction' as a third, non-monetary, but critical
    metric for measuring the success and adoption of AI tools.
  relevance_score: 7
  source: llm_enhanced
  text: Customer satisfaction with the end product is getting better, and the user
    satisfaction. So are our people happy with the tool we've given them? Yeah.
  topic: business
- impact_reason: Offers a positive perspective on regulatory segmentation (like the
    AI Act's risk levels), suggesting it aids in achieving industry consensus and
    adoption.
  relevance_score: 7
  source: llm_enhanced
  text: But those risk categories, especially the closer you get to insurance spaces,
    actually do a world of good at least in helping to segment different parts of
    the population, to segment different kinds of technology into categories that
    everybody is already accepting of and singing off more or less the same song sheet...
  topic: safety/regulation
- impact_reason: Generalizes the need for collaboration in generative AI beyond the
    specific industry context, suggesting it's a universal principle for GenAI adoption.
  relevance_score: 7
  source: llm_enhanced
  text: Still your point there of generative being an inherently collaborative technology,
    I think that has a lot of resonance far outside the life sciences space.
  topic: strategy
source: Unknown Source
summary: '## Podcast Episode Summary: AI ROI for Patient Insights and Better Eligibility
  Rates in Clinical Trials


  This 25-minute episode features Michael Zaiac, Head of Medical Oncology for Europe
  and Canada at Daiichi Sankyo, discussing the practical application of Artificial
  Intelligence (AI) within clinical trials, focusing specifically on accelerating
  recruitment and improving patient eligibility precision.


  ---


  ### 1. Focus Area

  The discussion centers on the application of AI/ML technologies in **clinical trial
  optimization**, specifically patient recruitment, matching, and diversity enhancement
  in oncology studies. It clearly differentiates between **deterministic AI (advanced
  analytics)** for pattern matching in patient identification and **generative AI**
  for patient-facing communications (e.g., consent forms, trial summaries). A significant
  theme is the pharmaceutical industry''s conservative, high-accuracy approach to
  AI deployment, heavily influenced by regulatory environments.


  ### 2. Key Technical Insights

  *   **Deterministic AI for Recruitment:** Advanced analytics (deterministic AI)
  is currently the primary driver for identifying trial-ready and diverse patient
  populations by leveraging pattern matching across Electronic Health Records (EHRs).

  *   **Generative AI for Patient Engagement:** Generative AI is being cautiously
  explored for adapting complex trial documentation into patient-friendly summaries,
  requiring significant restriction and validation to ensure regulatory compliance
  and prevent misinformation.

  *   **Intentional Model Restriction:** In pharma, the strategy for deploying powerful
  models (like LLMs) is often to make them *less* complex but *more* precise and restricted,
  ensuring high accuracy and adherence to safety standards, rather than maximizing
  general capability.


  ### 3. Business/Investment Angle

  *   **Clear ROI for Deterministic AI:** The ROI for deterministic AI in recruitment
  is immediate and quantifiable: faster enrollment leads to reduced study costs and
  earlier regulatory filing, resulting in longer market exclusivity.

  *   **Transparency as a Prerequisite for Acceptance:** Success in deploying AI requires
  extensive "pre-preparation"—a lengthy (sometimes nine-month equivalent) process
  of aligning legal, compliance, and regulatory stakeholders to ensure transparency
  and acceptance of the AI-generated outcomes.

  *   **Data Collaboration as the Bottleneck:** Despite technological readiness, the
  primary barrier to achieving future, faster trial timelines is the lack of sufficient,
  collaborative, high-quality data, particularly in Europe due to GDPR and competitive
  behavior among healthcare centers.


  ### 4. Notable Companies/People

  *   **Michael Zaiac (Daiichi Sankyo):** Guest expert, providing the perspective
  of a major global pharmaceutical company on AI adoption in clinical operations.

  *   **Daiichi Sankyo:** Highlighted as the second-largest pharmaceutical company
  in Japan, demonstrating leadership in applying advanced analytics in oncology trials.

  *   **Sam Altman:** Briefly referenced regarding the general observation that highly
  regulated industries like pharma are not the first adopters of cutting-edge AI technology.


  ### 5. Future Implications

  The industry is moving toward leveraging AI to create trials that perfectly mirror
  real-world patient populations, enhancing scientific validity. However, the pace
  of this advancement is currently constrained by **data infrastructure and collaboration**,
  rather than the AI software itself. Future success hinges on overcoming competitive
  barriers to data sharing, especially in regions like Europe.


  ### 6. Target Audience

  This episode is most valuable for **Pharmaceutical Executives, Clinical Operations
  Leaders, AI Strategy Leaders in Healthcare, and Regulatory/Compliance Officers**
  who are navigating the practical implementation, risk management, and ROI justification
  for AI technologies in regulated environments.'
tags:
- artificial-intelligence
- generative-ai
- investment
title: AI ROI for Patient Insights and Better Eligibility Rates in Clinical Trials
  - with Michael Zaiac of Daiichi Sankyo
topics:
- keywords:
  - ai
  - machine learning
  - deep learning
  - neural networks
  - llm
  - large language model
  mentions: 86
  prominence: 1.0
  topic: artificial intelligence
- keywords:
  - generative ai
  - genai
  - chatgpt
  - gpt
  - claude
  - text generation
  - image generation
  mentions: 10
  prominence: 1.0
  topic: generative ai
- keywords:
  - investment
  - funding
  - valuation
  - ipo
  - acquisition
  mentions: 2
  prominence: 0.2
  topic: investment
---

<!-- Episode automatically generated from analysis data -->
<!-- Processing completed: 2025-10-05 03:36:52 UTC -->
